Early Reexploration for Suspected Thrombosis After Pancreas Transplantation

Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Transplantation (Impact Factor: 3.83). 02/2011; 91(8):902-7. DOI: 10.1097/TP.0b013e3182106069
Source: PubMed


Graft thrombosis is the most common cause of early graft loss after pancreas transplantation. Early reexploration may permit salvage or timely removal of the thrombosed graft.
This was a retrospective review of 345 pancreas transplants performed at a single center between January 2003 and December 2009. Early reexploration was defined as within 1 week of pancreas transplantation.
Of the 345 transplants, there were 35 early reexplorations. The graft was compromised in 20 cases (57%): 10 venous thromboses, 3 arterial thromboses, 2 combined arterial and venous thrombosis, 2 thromboses secondary to allograft pancreatitis, and 3 cases of positional ischemia without thrombosis. Of these allografts, three reperfused once repositioned and six were successfully thrombectomized for a graft salvage rate of 45%. One of the thrombectomized grafts remained perfused but never functioned and was removed at retransplantation. The 10 remaining compromised grafts that were deemed unsalvageable and required allograft pancreatectomy. Nine of these recipients were retransplanted (eight within 2 weeks) and one was not a retransplantation candidate.
Reexploration for suspected graft thrombosis after pancreas transplantation resulted in a negative laparotomy rate of 43%, but permitted graft salvage in 45% of compromised grafts.

Download full-text


Available from: Richard S Mangus, Nov 28, 2014
21 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreas graft thrombosis remains one of the most common reasons for pancreas transplant loss. Patients with a history of thrombotic events should be identified and evaluated for thrombophilia to identify transplant candidates at highest risk. Early after transplant, vascular thrombosis is multifactorial, but beyond 2 weeks, inflammation or acute rejection predominate as the cause of thrombosis. Most pancreas transplant centers utilize some form of anticoagulation following transplantation. Aspirin is highly recommended. Unfractionated or low-molecular-weight heparin is often administered, but some centers use heparin selectively and typically at low dose to avoid postoperative bleeding. Warfarin is less frequently given and its use should probably be limited to patients with thrombophilia. Thrombectomy, either surgical or percutaneous, may salvage the pancreas graft if performed early after the occurrence of thrombosis.
    Current opinion in organ transplantation 12/2011; 17(1):87-92. DOI:10.1097/MOT.0b013e32834ee717 · 2.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Simultaneous pancreas-kidney transplantation (SPKT) is a promising therapy for type 1 diabetes mellitus with chronic kidney disease. Although the long-term outcome of SPKT is extensively documented, the incidence of early complications within the first weeks after the surgery is less described. The aim of this study was to assess the incidence, causes, and risk factors of early relaparotomy after SPKT. All SPKT performed in the university hospital between 2005 and 2008 were enrolled. The primary endpoint was defined as the need for at least one relaparotomy after SPKT within the initial hospital stay. The secondary endpoints were the incidence of vascular graft thrombosis, postoperative sepsis, patient, and graft survival. Sixty-one patients were included. During their initial hospital stay, 27 (44.3%) SPKT recipients required at least one relaparotomy. The main causes of relaparotomy were hemorrhage (59.3%) and vascular graft thrombosis (22.2%). First relaparotomy occurred at a median postoperative time of 1 day (interquartile range, 1-6). Pretransplant dialysis and nontraumatic cause of donor brain death were identified as independent risk factors for early relaparotomy. Thirty-two patients (52.4%) experienced a symptomatic or asymptomatic vascular graft thrombosis. The early postoperative period remains a high-risk phase for relaparotomy. The selection of recipients before initiation of long-term dialysis and of donors deceased from traumatic causes may reduce the rate of these early complications after SPKT. Vascular graft thrombosis and bleeding are two major issues that arise during this critical period, suggesting the importance an adequate management of postoperative anticoagulation and hemostasis.
    Transplantation 06/2012; 94(2):159-64. DOI:10.1097/TP.0b013e318254dae1 · 3.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: To determine factors associated with early pancreatic allograft thrombosis (EPAT). Thrombosis is the leading non-immunological cause of early pancreatic allograft failure. Multiple risk factors have been postulated. We hypothesized that recipient perioperative hypotension was a major risk factor and evaluated the correlation of this and other parameters with EPAT. Methods: We retrospectively reviewed the records of the 118 patients who received a pancreatic allograft at our center between October 1992 and January 2010. Multiple donor and recipient parameters were analyzed as associates of EPAT by univariate and multivariate analysis. Results: There were 12 episodes of EPAT, resulting in an incidence of 10.2%. On univariate analysis, EPAT was associated with perioperative hypotension, vasopressor use, and neuropathy in the recipient (p ≤ 0.04 for all). On multivariate analysis corrected for age, sex, and peripheral vascular disease, only vasopressor use retained a significant association with EPAT with a hazard ratio of 8.74 (CI 1.11-68.9, p = 0.04). Factors associated with vasopressor use included recipient ischemic heart disease, peripheral vascular disease, retinopathy or neuropathy, and any surgical complication. Conclusions: Significant hypotension, measured by the need for perioperative vasopressor use was associated with EPAT, suggesting that maintenance of higher perfusion pressures may avoid this complication.
    Clinical Transplantation 03/2013; 27(3). DOI:10.1111/ctr.12105 · 1.52 Impact Factor
Show more